Vigil Neuroscience (NASDAQ:VIGL) Cut to Hold at Mizuho

Vigil Neuroscience (NASDAQ:VIGL) was downgraded by stock analysts at Mizuho from a “strong-buy” rating to a “hold” rating in a research report issued on Friday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the stock. Citizens Jmp downgraded shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Thursday. JMP Securities reaffirmed a “market perform” rating on shares of Vigil Neuroscience in a research note on Thursday. William Blair downgraded shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. Citigroup downgraded shares of Vigil Neuroscience to a “market perform” rating in a research note on Thursday. Finally, HC Wainwright dropped their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.00.

Vigil Neuroscience Price Performance

Shares of VIGL stock opened at $7.89 on Friday. The company has a market cap of $368.24 million, a PE ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The stock’s 50 day simple moving average is $2.19 and its two-hundred day simple moving average is $2.30.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. Equities research analysts expect that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL grew its stake in Vigil Neuroscience by 121.3% in the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company’s stock worth $7,144,000 after acquiring an additional 2,200,000 shares in the last quarter. 683 Capital Management LLC raised its stake in shares of Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company’s stock valued at $3,097,000 after acquiring an additional 340,000 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of Vigil Neuroscience by 226.3% in the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock valued at $3,070,000 after purchasing an additional 1,196,048 shares during the period. Blair William & Co. IL boosted its holdings in shares of Vigil Neuroscience by 219.1% in the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock valued at $1,840,000 after purchasing an additional 709,677 shares during the period. Finally, Woodline Partners LP grew its stake in Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after purchasing an additional 344,614 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.